Comparative effects of glibenclamide and metformin on c-reactive protein and oxidant/antioxidant status in patients with type ii diabetes mellitus

Sultan Qaboos University Medical Journal

Volumn 12, Issue 1, 2012, Pages 606-612

  Abdulkadir, Alaa A A ^a   Thanoon, Imad A J ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

Author keywords

Diabetes mellitus; Glibenclamide; High sensitivity serum c reactive protein (hs CRP); Malondialdehyde (MDA); Metformin; Total antioxidant status (TAS)

Indexed keywords

EID: 84857084492     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.12816/0003088     Document Type: Article

References (36)

1. Meigs JB, Larson MG, Fox CS, Keaney JF, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance and diabetes. Risk phenotype: The Framingham offspring study. Diabetes Care study. Diabetes Care 2007; 30:2529-35.
2. Wang Z, Hoy EH. C-reactive protein and the risk of developing type 2 diabetes in aboriginal Australians. Diabetes Res Clin Pract 2007; 76:37-43.
3. Wen J, Liang Y, Wang F, Sun L, Guo Y, Duan X, et al. C-reactive protein, gamma-glutamyltransferase and type 2 diabetes in a Chinese population. Clin Chim Acta 2010; 411:198-203.
4. Jin Y, Han G, Hu Y, Bi Y, Li L, Zhu D. Tea consumption and risk of type 2 diabetes: A meta-analysis of cohort studies. J Gen Intern Med 2009; 24:557-62.
5. Medina-Navarro R, Duran-Reyes G, Diaz-Flores M, Vilar-Rojas C. Protein antioxidant response to the stress and the relationship between molecular structure and antioxidant function. PLoS One 2010; 5:8971.
6. Yamanouchi T, Taniguchi A, Fukushima M, Nakai Y, Nagasaka S, Ohgushi M, et al. Leptin, triglyceride, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diabetes Rese Clin Pract 2007; 75:2-6.
7. Ahmed KA, Muniandy S, Ismail IS. N ε-(carboxymethyl) lysine and coronary atherosclerosis-associated low density lipoprotein abnormalities in type 2 diabetes: Current status. J Clin Biochem Nutr 2009; 44:14-27.
8. Nistala R, Whaley-Connell A, Sower JR. Redox control of renal function and hypertension. Antioxid Redox Signal 2008; 10:2047-89.
9. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once daily extended release metformin in patients with type 2 diabetes mellitus. Diabet Metab Syndr 2010; 2:16.
10. Shimabukuro MT, Higa N, Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in type 2 diabetic patients. A randomized crossover study. J Diabet Complications 2006; 20:179-83.
11. WHO (World Health Organization). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/ IDF consultation. Geneva: WHO Document Production Services, 2006. Pp. 1-41.
12. ADA (American Diabetes Association). Standards of Medical Care in Diabetes, 2010: Position Statement. Diabet Care 2010; 33:S11-61.
13. Cummings PJ. Immunoassay. In: Appleton and Lange's Outline Review: Clinical Chemistry. New York: McGraw-Hill Companies 2001. Pp. 310-15.
14. Buege JA, Aust SD. Thiobarbituric acid assay. Methods Enzymol 1978; 52:306-07.
15. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84:407-12.
16. Leermarkers EA, Dunn AL, Blaire SN. Exercise management of obesity. Med Clin North Am 2000; 84:419-25.
17. Kirkwood BR. Essentials of Medical Statistics.1st ed. Oxford: Blackwell Scientific Publications, 1988. Pp. 43-56.
18. Jager JD, Kooy A, Lehert PH, Bets D, Wulffele MG, Teerlink T, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo controlled trial. J Int Med 2005; 257:100-9.
19. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153:445 e1-6.
20. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: The Lancet randomized trial. JAMA 2009; 302: 1186-94.
21. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, et al. The influence of improved glycemic control with insulin and sulphonylureas on acute phase and endothelial markers in type 2 diabetic subjects. Diabetologia 2000; 43:1099-106.
22. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010; 12:233-40.
23. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome. Endocrine 2003; 20:215-18.
24. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: Observation from a diabetes outcome progression trial (ADOPT). Diabet Care 2010; 33:177-183.
25. Singh U, Jialal I. Alpha-lipoic acid supplementation and Diabetes. Nutr Rev 2008; 66:646-57.
26. Mahreen R, Mohsin M, Nasreen Z, Siraj M, Ishaq M. Significantly increased levels of serum malondialdehyde in type 2 diabetes with myocardial infarction. Int J Diabetes Dev Ctries 2010; 30:40-51.
27. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocystine levels in lean patients with polycystic ovary syndrome. Human Reproduct 2005; 20:3333-40.
28. Pavlović D, Kocić R, Kocić G, Jevtović T, Radenković S, Mikić D, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2:251-256.
29. Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999; 48:897-903.
30. Skrha J, Prazny M, Hilgertova J, Kvasnicka J, Kalousova M, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007; 63:1107-14.
31. Gupta RK, Rehan HS, Rohatagi A, Bhatacharjee J, Chopra D. The effect of glipizide, metformin and rosiglitazone on nontraditional cardiovascular risk factors in newly diagnosed patients with type 2 diabetes mellitus. Int J Diabetes Dev Ctries 2010; 30:123-8.
32. Stefanovic V, Antic S, Milojkovic M, Lazarević G, Vlahovic P. Lymphocyte ecto-5-nucleotidase in obese type 2 diabetic patients treated with gliclazide. Diabetes Metab 2006; 32:166-70.
33. Chugh SN, Dhawan R, Kishore K, Sharma A, Chugh K. Glibenclamide vs gliclazide in reducing oxidative stress in patients of non insulin dependent diabetes mellitus. A double blind randomized study. J Assoc Physicians India 2001; 49:803-7.
34. Jennings PE, Scott NA, Saniabadi AR, Belch JJ. Effects of gliclazide on platelet reactivity and free radicals in type 2 diabetic patients: Clinical assessment. Metabol 1992; 41:36-9.
35. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci 2008; 114:251-6.
36. Lima LMA, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in firstdegree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrin. Clin Sci 2009; 64:415-20.